Madrigal Pharmaceuticals Inc (NAS:MDGL)
$ 229.58 -5.27 (-2.24%) Market Cap: 4.89 Bil Enterprise Value: 3.95 Bil PE Ratio: 0 PB Ratio: 5.58 GF Score: 44/100

Madrigal Pharmaceuticals Inc EASL Investor Event Call Transcript

Jun 25, 2022 / 07:00PM GMT
Paul A. Friedman
Madrigal Pharmaceuticals, Inc. - Chairman & CEO

So thank you all for coming. And for those who have joined on the webcast, welcome. With me today, I have Dr. Becky Taub, President of R&D and Chief Medical Officer of Madrigal; and Stephen Harrison needs no introduction, lead investigator of our Phase III MAESTRO studies, resmetirom.

Please see today's press release, unless you want to memorize this for our forward-looking statements and I ask you to look at the press release today and our SEC filings for forward-looking statements and risk factor considerations associated with these statements and our business. The EASL 2022 International Liver Congress has been a busy time for Madrigal. Earlier today, we presented late-breaking data from our Phase III MAESTRO-NAFLD-1 safety study of resmetirom. This was the first presentation of the double-blind results in a major scientific meeting and we're going to review some of that data shortly. We and our collaborators presented 3 additional oral abstracts and 2 posters among the oral abstracts or analyses of new data from the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot